A phase 2 study of ASC42, a novel farnesoid X receptor (FXR) agonist, in combination with PEGylated interferon (PEG-IFN) and entecavir(ETV) in chronic hepatitis B patients with 12-week treatment
Journal of Hepatology（2023）
关键词
hepatitis,fxr,receptor,peg-ifn
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要